PDF(Pubmed)
Abstract：
BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health problem all over the world. After the 2019 coronavirus illness (COVID-19), the pandemic may have influenced research priorities and resource allocation, potentially affecting the ability to monitor MRSA trends.
OBJECTIVE: The study aimed to evaluate the prevalence of S. aureus, including MRSA infections, and their antimicrobial susceptibilities over the years 2019 and 2020 in a tertiary hospital in Makkah City, KSA.
METHODS: A total of 2128 and 1515 laboratory (lab) samples were collected during the years 2019 and 2020, respectively. From these samples, the prevalence of S. aureus, including MRSA, and their antibiotic susceptibility were identified using standard, automated, and molecular microbiological methods.
RESULTS: The present study shows that the lab prevalence of all S. aureus during 2019 was found to be 35.5%, of which MRSA was 44.8%. During 2020, the frequency of S. aureus strains was 16%, of which MRSA was 41.2%. The most common MRSA isolated during both years were colonizing pus swabs and urine samples. The results showed that MRSA susceptibility against antimicrobial agents in 2019 was as follows: vancomycin (100%), linezolid (100%), trimethoprim-sulfamethoxazole (88%), and doxycycline (34.2%). The MRSA strains isolated during 2020 were as follows: vancomycin (100%), linezolid (96%), trimethoprim-sulfamethoxazole (100%), and doxycycline (24.3%). There was no significant difference in the incidence and antimicrobial resistance rates of MRSA over the two years.
CONCLUSIONS: It was concluded that the prevalence rates of MRSA have not increased in 2020 when compared to 2019. Vancomycin, linezolid, trimethoprim-sulfamethoxazole, and doxycycline remain susceptible to the positive collected MRSA strains. There was no significant difference between the prevalence and antimicrobial resistance rates of MRSA between 2019 and 2020. Continued research efforts are needed to address this persistent public health threat. Strategies to control the spread of MRSA should include early detection of MRSA and surveillance, even during pandemics.
OBJECTIVE: The study aimed to evaluate the prevalence of S. aureus, including MRSA infections, and their antimicrobial susceptibilities over the years 2019 and 2020 in a tertiary hospital in Makkah City, KSA.
METHODS: A total of 2128 and 1515 laboratory (lab) samples were collected during the years 2019 and 2020, respectively. From these samples, the prevalence of S. aureus, including MRSA, and their antibiotic susceptibility were identified using standard, automated, and molecular microbiological methods.
RESULTS: The present study shows that the lab prevalence of all S. aureus during 2019 was found to be 35.5%, of which MRSA was 44.8%. During 2020, the frequency of S. aureus strains was 16%, of which MRSA was 41.2%. The most common MRSA isolated during both years were colonizing pus swabs and urine samples. The results showed that MRSA susceptibility against antimicrobial agents in 2019 was as follows: vancomycin (100%), linezolid (100%), trimethoprim-sulfamethoxazole (88%), and doxycycline (34.2%). The MRSA strains isolated during 2020 were as follows: vancomycin (100%), linezolid (96%), trimethoprim-sulfamethoxazole (100%), and doxycycline (24.3%). There was no significant difference in the incidence and antimicrobial resistance rates of MRSA over the two years.
CONCLUSIONS: It was concluded that the prevalence rates of MRSA have not increased in 2020 when compared to 2019. Vancomycin, linezolid, trimethoprim-sulfamethoxazole, and doxycycline remain susceptible to the positive collected MRSA strains. There was no significant difference between the prevalence and antimicrobial resistance rates of MRSA between 2019 and 2020. Continued research efforts are needed to address this persistent public health threat. Strategies to control the spread of MRSA should include early detection of MRSA and surveillance, even during pandemics.
摘要：
背景：耐甲氧西林金黄色葡萄球菌（MRSA）已成为世界范围内的主要公共卫生问题。在2019年冠状病毒病（COVID-19）之后，大流行可能影响了研究重点和资源分配，可能影响监测MRSA趋势的能力。
目的：本研究旨在评估金黄色葡萄球菌的患病率，包括MRSA感染,以及它们在2019年和2020年在麦加市一家三级医院的抗菌敏感性，KSA
方法：在2019年和2020年共收集了2128和1515个实验室（实验室）样本。从这些样本中,金黄色葡萄球菌的患病率，包括MRSA,他们的抗生素敏感性是用标准方法鉴定的，自动化,和分子微生物学方法。
结果：本研究表明，2019年所有金黄色葡萄球菌的实验室患病率为35.5%，其中MRSA占44.8%。在2020年，金黄色葡萄球菌菌株的频率为16%，其中MRSA占41.2%。在这两年中分离出的最常见的MRSA是定植的脓拭子和尿液样本。结果显示，2019年MRSA对抗菌药物的敏感性如下：万古霉素（100%）、利奈唑胺(100%),甲氧苄啶-磺胺甲恶唑（88%），和多西环素(34.2%)。2020年分离的MRSA菌株如下：万古霉素(100%)，利奈唑胺（96%），甲氧苄啶-磺胺甲恶唑(100%)，和多西环素(24.3%)。两年来，MRSA的发病率和耐药性没有显着差异。
结论：结论是，与2019年相比，2020年MRSA的患病率没有增加。万古霉素,利奈唑胺,甲氧苄啶-磺胺甲恶唑,多西环素对收集的MRSA阳性菌株仍然敏感。2019年至2020年MRSA的患病率和耐药性之间没有显着差异。需要持续的研究努力来解决这种持续存在的公共卫生威胁。控制MRSA传播的策略应包括早期发现MRSA和监测，即使在大流行期间。
目的：本研究旨在评估金黄色葡萄球菌的患病率，包括MRSA感染,以及它们在2019年和2020年在麦加市一家三级医院的抗菌敏感性，KSA
方法：在2019年和2020年共收集了2128和1515个实验室（实验室）样本。从这些样本中,金黄色葡萄球菌的患病率，包括MRSA,他们的抗生素敏感性是用标准方法鉴定的，自动化,和分子微生物学方法。
结果：本研究表明，2019年所有金黄色葡萄球菌的实验室患病率为35.5%，其中MRSA占44.8%。在2020年，金黄色葡萄球菌菌株的频率为16%，其中MRSA占41.2%。在这两年中分离出的最常见的MRSA是定植的脓拭子和尿液样本。结果显示，2019年MRSA对抗菌药物的敏感性如下：万古霉素（100%）、利奈唑胺(100%),甲氧苄啶-磺胺甲恶唑（88%），和多西环素(34.2%)。2020年分离的MRSA菌株如下：万古霉素(100%)，利奈唑胺（96%），甲氧苄啶-磺胺甲恶唑(100%)，和多西环素(24.3%)。两年来，MRSA的发病率和耐药性没有显着差异。
结论：结论是，与2019年相比，2020年MRSA的患病率没有增加。万古霉素,利奈唑胺,甲氧苄啶-磺胺甲恶唑,多西环素对收集的MRSA阳性菌株仍然敏感。2019年至2020年MRSA的患病率和耐药性之间没有显着差异。需要持续的研究努力来解决这种持续存在的公共卫生威胁。控制MRSA传播的策略应包括早期发现MRSA和监测，即使在大流行期间。
